ATE258935T1 - Furo(3,2-b)pyridine als 5-ht1f agonisten - Google Patents

Furo(3,2-b)pyridine als 5-ht1f agonisten

Info

Publication number
ATE258935T1
ATE258935T1 AT00911678T AT00911678T ATE258935T1 AT E258935 T1 ATE258935 T1 AT E258935T1 AT 00911678 T AT00911678 T AT 00911678T AT 00911678 T AT00911678 T AT 00911678T AT E258935 T1 ATE258935 T1 AT E258935T1
Authority
AT
Austria
Prior art keywords
furo
pyridines
ht1f agonists
ht1f
agonists
Prior art date
Application number
AT00911678T
Other languages
English (en)
Inventor
Sandra Ann Filla
Brian Michael Mathes
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE258935T1 publication Critical patent/ATE258935T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT00911678T 1999-02-26 2000-02-11 Furo(3,2-b)pyridine als 5-ht1f agonisten ATE258935T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12201699P 1999-02-26 1999-02-26
PCT/US2000/002505 WO2000050426A2 (en) 1999-02-26 2000-02-11 Furo[3, 2-b]pyridines as 5-ht1f agonists

Publications (1)

Publication Number Publication Date
ATE258935T1 true ATE258935T1 (de) 2004-02-15

Family

ID=22400069

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00911678T ATE258935T1 (de) 1999-02-26 2000-02-11 Furo(3,2-b)pyridine als 5-ht1f agonisten

Country Status (21)

Country Link
EP (1) EP1155020B1 (de)
JP (1) JP2002537398A (de)
KR (1) KR20010102355A (de)
AR (1) AR026856A1 (de)
AT (1) ATE258935T1 (de)
AU (1) AU3354000A (de)
BR (1) BR0008479A (de)
CA (1) CA2371784A1 (de)
CO (1) CO5150234A1 (de)
DE (1) DE60008073T2 (de)
EA (1) EA200100918A1 (de)
ES (1) ES2214256T3 (de)
HU (1) HUP0200245A2 (de)
ID (1) ID30056A (de)
IL (1) IL144355A0 (de)
NO (1) NO20014127L (de)
PE (1) PE20001432A1 (de)
PL (1) PL350864A1 (de)
TR (1) TR200102436T2 (de)
WO (1) WO2000050426A2 (de)
ZA (1) ZA200106109B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
JP2006523692A (ja) 2003-04-18 2006-10-19 イーライ リリー アンド カンパニー ５−ｈｔ１ｆ作用薬としての（ピペリジニルオキシ）フェニル、（ピペリジニルオキシ）ピリジニル、（ピペリジニルスルファニル）フェニル、および（ピペリジニルスルファニル）ピリジニル化合物
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
EP1697305B1 (de) 2003-12-17 2007-08-15 Eli Lilly And Company Substituierte (4-aminocyclohexen-1-yl) phenyl and (4-aminocyclohexen-1-yl) pyridinyl verbindungen als 5-ht1f agonisten
JP5727457B2 (ja) 2009-04-02 2015-06-03 コルーシッド ファーマシューティカルズ， インコーポレイテッド ２，４，６−トリフルオロ−ｎ−［６−（１−メチル−ピペリジン−４−カルボニル）−ピリジン−２−イル］−ベンズアミドの組成物
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
EP2940022B1 (de) * 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridinen als Inhibitoren von Proteinkinasen
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
AR119319A1 (es) 2019-07-09 2021-12-09 Lilly Co Eli Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980703048A (ko) * 1995-03-20 1998-09-05 피터쥐.스트링거 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1ｈ-인돌: 신규한 5-ｈｔ1ｆ 아고니스트
FR2732969B1 (fr) * 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU4074897A (en) * 1996-09-18 1998-04-14 Eli Lilly And Company A method for the prevention of migraine

Also Published As

Publication number Publication date
PE20001432A1 (es) 2000-12-18
NO20014127D0 (no) 2001-08-24
PL350864A1 (en) 2003-02-10
JP2002537398A (ja) 2002-11-05
BR0008479A (pt) 2002-01-29
HUP0200245A2 (en) 2002-06-29
ES2214256T3 (es) 2004-09-16
IL144355A0 (en) 2002-05-23
AU3354000A (en) 2000-09-14
WO2000050426A2 (en) 2000-08-31
CA2371784A1 (en) 2000-08-31
DE60008073T2 (de) 2004-08-05
EP1155020B1 (de) 2004-02-04
ZA200106109B (en) 2002-07-25
NO20014127L (no) 2001-08-24
ID30056A (id) 2001-11-01
WO2000050426A3 (en) 2000-12-21
EA200100918A1 (ru) 2002-02-28
CO5150234A1 (es) 2002-04-29
AR026856A1 (es) 2003-03-05
KR20010102355A (ko) 2001-11-15
EP1155020A2 (de) 2001-11-21
DE60008073D1 (de) 2004-03-11
TR200102436T2 (tr) 2002-06-21

Similar Documents

Publication Publication Date Title
PT1343786E (pt) Novos derivados de pirazolopiridina substituidos por piridina
DE60202200D1 (de) Imidazo[1,2-a]-pyridinderivate als mglur5 antagonisten
PT1218378E (pt) Derivados de terc-butil-(7-metil-imidazo-¬1,2-a|-piridin-3-il)-amina
ATE293618T1 (de) 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel
DZ3216A1 (fr) Inhibiteurs tricycliques de poly(adp-ribose) polymerases
HRP20030306A2 (en) Pyridine derivatives with ikb-kinase (ikk-?) inhibiting activity
DE60214428D1 (de) 1, 4-dihydro-1, 4-diphenylpyridin-derivate
ITMI20002358A0 (it) Derivati di tieno [2,3-c]isochinolin-3-one come inibitori della poli(adp-ribosio)polimerasi
DE60021371D1 (de) Piperidinderivate verwendbar als ccr5 antagonisten
DK1254118T3 (da) Substituerede 1,2,3,4-tetrahudroquinolin-2-carboxylsyrederivater
ATE270294T1 (de) 1,2,3,4-tetrahydro-benzofuro(3,2-c)pyridin derivate
DE60008073D1 (de) Furo[3,2-b]pyridine als 5-ht1f agonisten
NO20005485D0 (no) Orale preparater inneholdende 8-klor-6,11-dihydro-11-(4- piperyliden)-5H-benzo-[5,6]syklohepta[1,2-b]pyridin
NO20004892D0 (no) Kinolin-4-yl-derivater I
DE60001054D1 (de) Trizyclische pyridin n-oxide vasopressin agonisten
AU7845701A (en) Heterocyclic aminoalkyl pyridine derivatives as psychopharmaceuticals
DK1088818T3 (da) Quinolin-4-yl-derivater
PT1317430E (pt) Derivados de (2-azabiciclo[2.2.1]hepta-7-il)-metanol como agonistas do receptor nocotinico de acetilcolina
ATE363485T1 (de) Benzothieno(3,2-c)pyridine als alpha2- antagonisten
PT1192163E (pt) Ditiepino¬6,5-b|piridinas e composicoes e metodos relacionados
EE04372B1 (et) 5-asendatud-3-oksadiasolüül-1,6-naftüridiin-2(1H)-ooni derivaadid
ID30349A (id) Turunan benzo (5,6) siklohepta (1,2-b) piridin untuk menghambat transferase protein farnesil
EP1359912A4 (de) Neue verfahren zur anwendung von pyridinderivaten
NO20031412L (no) Substituerte 3,4-dihydro-pyrido[1,2-A]pyrimidiner
SK2226U (sk) Jablkovobazová šťava

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties